Related Experiment Video
Updated: Aug 8, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
Hepatitis C and HIV co-infection
1Regional Infectious Diseases Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
Insights
HIV accelerates liver disease in hepatitis C virus (HCV) patients. More research is needed on managing co-infections, optimizing treatment, and improving HCV therapies for better immune recovery.
Area of Science:
- Hepatology
- Infectious Diseases
- Immunology
Background:
- HIV infection accelerates liver disease progression in patients with hepatitis C virus (HCV).
- Conflicting data exist regarding HCV's impact on HIV progression and CD4+ T-cell response to antiretroviral therapy.
- Optimal management strategies for HIV-HCV co-infected patients remain unclear.
Purpose of the Study:
- To address the need for long-term prospective studies on HIV-HCV co-infection.
- To clarify the effect of HCV on HIV progression and CD4+ T-cell recovery.
- To evaluate optimal highly active antiretroviral therapy (HAART) regimens for co-infected patients.
Main Methods:
- Long-term prospective cohort studies are required.
- Further research into immune CD4 recovery and adverse reactions to HAART in co-infected patients.
Main Results:
- Current HCV treatments have significant side effects, limiting their use in many HIV co-infected patients.
- Patients with higher CD4 counts and HCV genotypes 2 or 3 show potential for treatment response.
Conclusions:
- Urgent need for improved, interferon-free HCV treatments for HIV co-infected individuals.
- Further research is essential to optimize HAART and HCV treatment strategies for co-infected patients.
Abstract:
HIV accelerates progression of hepatitis C virus (HCV)-related liver disease. There are conflicting data on the effect of HCV on the risk of HIV progression and CD4 response to highly active antiretroviral therapy (HAART). Long-term prospective cohort studies are clearly required to resolve these issues. The optimal management of the co-infected patient is also unclear. For the co-infected patient, the optimal HAART regimen for best immune CD4 recovery and least adverse reactions remains unclear. Unfortunately, current HCV treatment is associated with significant side effects and a considerable proportion of HIV co-infected patients are poor candidates for HCV treatment. Better and more effective treatment for HCV (preferably not based on interferon) is urgently required for this group of patients. Patients with good CD4 cell count and with HCV genotypes 2 and 3 are likely to have a reasonable response to treatment.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Sexually Transmitted Infections
Cytomegalovirus Disease
Hepatitis
Viral Hepatitis I: Introduction

